Tesaro UK Limited - نتائج البحث

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

pluvicto

novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostatic neoplasmer, kastration-resistent - terapeutiske radioaktive lægemidler - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

azarga

novartis europharm limited - brinzolamid, timolol maleate - glaucoma, open-angle; ocular hypertension - oftalmologiske - reduktion af intraokulært tryk (iop) hos voksne patienter med åbenvinklet glaukom eller okulær hypertension, for hvem monoterapi giver utilstrækkelig iop reduktion.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

ypozane

virbac s.a. - osateronacetat - urologicals - hunde - behandling af godartet prostatisk hypertrofi (bph) hos hanhunde.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

krystexxa

crealta pharmaceuticals ireland limited - pegloticase - gigt - antigout præparater - krystexxa er indiceret til behandling af svær invaliderende kroniske tophaceous gigt i voksne patienter der kan have erosive fælles engagement og der har ikke kunnet normalisere serum urinsyre med xanthin oxidase hæmmere på maksimalt lægeligt passende dosis eller for hvem disse lægemidler er kontraindiceret.